Head-To-Head Comparison: Clever Leaves (NASDAQ:CLVR) versus Avenue Therapeutics (NASDAQ:ATXI)

Insider and Institutional Ownership

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Clever Leaves and Avenue Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Avenue Therapeutics	N/A	-471.57%	-296.50%

Earnings and Valuation

This table compares Clever Leaves and Avenue Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42 million	0.00	-$17.90 million	($12.36)	0.00
Avenue Therapeutics	N/A	N/A	-$10.38 million	($0.94)	-0.70

Avenue Therapeutics has lower revenue, but higher earnings than Clever Leaves. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Clever Leaves has a beta of 4212.86, suggesting that its stock price is 421,186% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.92, suggesting that its stock price is 192% less volatile than the S&P 500.

Summary

Avenue Therapeutics beats Clever Leaves on 5 of the 9 factors compared between the two stocks.

About Clever Leaves

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

About Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.